3rd Oct 2013 08:33
LONDON (Alliance News) - Healthcare company BTG PLC Thursday raised its full-year revenue guidance due to recent acquisitions it has made and said its performance the first half of the year had met its expectations.
It said it now expects revenues in the year to March 31, 2014 to be between GBP275 million and GBP285 million, up from previous guidance of between GBP235 million and GBP245 million, after making progress in integrating the targeted therapies division of Nordion Inc., and EKOS Corporation, deals that completed in July.
In a trading update, the company said new varicose vein treatment Varisolve is still progressing through a new drug application review in the US, and it is pushing ahead with preparations for a commercial launch in the first six months of the 2014 calendar year.
"We have made a strong start to the year with a good financial performance across our operating segments," BTG Chief Executive Louise Makin said in a statement. "Overall, the business is in great shape and we look forward to continued progress in the second half year."
BTG shares were up 1.7% at 387 pence, one of the biggest risers on the FTSE 250.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
BTG